Impact of Imprinted Immunity Induced by mRNA Vaccination in an Experimental Animal Model

Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron subvariants. The concept of “imprinted immunity” suggests that individuals vaccinat...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 228; no. 8; pp. 1060 - 1065
Main Authors Fujita, Shigeru, Uriu, Keiya, Pan, Lin, Nao, Naganori, Tabata, Koshiro, Kishimoto, Mai, Itakura, Yukari, Sawa, Hirofumi, Kida, Izumi, Tamura, Tomokazu, Fukuhara, Takasuke, Ito, Jumpei, Matsuno, Keita, Sato, Kei
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 18.10.2023
Subjects
Animal models
Antiviral drugs
Brief Report
Coronaviruses
Humoral immunity
Immunity
mRNA
Nanoparticles
Severe acute respiratory syndrome coronavirus 2
Vaccines
SARS-CoV-2
omicron
imprinted immunity
mRNA vaccine
Omicron
Online AccessGet full text

Cover

Abstract Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron subvariants. The concept of “imprinted immunity” suggests that individuals vaccinated with ancestral virus-based vaccines may not develop effective immunity against newly emerging Omicron subvariants, such as BQ.1.1 and XBB.1. In this study, we investigated this possibility using hamsters. Although natural infection induced effective antiviral immunity, breakthrough infections in hamsters with BQ.1.1 and XBB.1 Omicron subvariants after receiving the 3-dose mRNA-lipid nanoparticle vaccine resulted in only faintly induced humoral immunity, supporting the possibility of imprinted immunity. The emergence of SARS-CoV-2 Omicron XBB subvariants raises vaccine effectiveness concerns. Our hamster model demonstrated that ancestral virus-based vaccines failed to produce effective neutralizing antibodies against Omicron subvariants (eg, BQ.1.1, XBB.1) during breakthrough infections, supporting the concept of imprinted immunity.
AbstractList Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron subvariants. The concept of “imprinted immunity” suggests that individuals vaccinated with ancestral virus-based vaccines may not develop effective immunity against newly emerging Omicron subvariants, such as BQ.1.1 and XBB.1. In this study, we investigated this possibility using hamsters. Although natural infection induced effective antiviral immunity, breakthrough infections in hamsters with BQ.1.1 and XBB.1 Omicron subvariants after receiving the 3-dose mRNA-lipid nanoparticle vaccine resulted in only faintly induced humoral immunity, supporting the possibility of imprinted immunity. The emergence of SARS-CoV-2 Omicron XBB subvariants raises vaccine effectiveness concerns. Our hamster model demonstrated that ancestral virus-based vaccines failed to produce effective neutralizing antibodies against Omicron subvariants (eg, BQ.1.1, XBB.1) during breakthrough infections, supporting the concept of imprinted immunity.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron subvariants. The concept of “imprinted immunity” suggests that individuals vaccinated with ancestral virus-based vaccines may not develop effective immunity against newly emerging Omicron subvariants, such as BQ.1.1 and XBB.1. In this study, we investigated this possibility using hamsters. Although natural infection induced effective antiviral immunity, breakthrough infections in hamsters with BQ.1.1 and XBB.1 Omicron subvariants after receiving the 3-dose mRNA-lipid nanoparticle vaccine resulted in only faintly induced humoral immunity, supporting the possibility of imprinted immunity.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron subvariants. The concept of “imprinted immunity” suggests that individuals vaccinated with ancestral virus-based vaccines may not develop effective immunity against newly emerging Omicron subvariants, such as BQ.1.1 and XBB.1. In this study, we investigated this possibility using hamsters. Although natural infection induced effective antiviral immunity, breakthrough infections in hamsters with BQ.1.1 and XBB.1 Omicron subvariants after receiving the 3-dose mRNA-lipid nanoparticle vaccine resulted in only faintly induced humoral immunity, supporting the possibility of imprinted immunity. The emergence of SARS-CoV-2 Omicron XBB subvariants raises vaccine effectiveness concerns. Our hamster model demonstrated that ancestral virus-based vaccines failed to produce effective neutralizing antibodies against Omicron subvariants (eg, BQ.1.1, XBB.1) during breakthrough infections, supporting the concept of imprinted immunity.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron subvariants. The concept of "imprinted immunity" suggests that individuals vaccinated with ancestral virus-based vaccines may not develop effective immunity against newly emerging Omicron subvariants, such as BQ.1.1 and XBB.1. In this study, we investigated this possibility using hamsters. Although natural infection induced effective antiviral immunity, breakthrough infections in hamsters with BQ.1.1 and XBB.1 Omicron subvariants after receiving the 3-dose mRNA-lipid nanoparticle vaccine resulted in only faintly induced humoral immunity, supporting the possibility of imprinted immunity.The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron subvariants. The concept of "imprinted immunity" suggests that individuals vaccinated with ancestral virus-based vaccines may not develop effective immunity against newly emerging Omicron subvariants, such as BQ.1.1 and XBB.1. In this study, we investigated this possibility using hamsters. Although natural infection induced effective antiviral immunity, breakthrough infections in hamsters with BQ.1.1 and XBB.1 Omicron subvariants after receiving the 3-dose mRNA-lipid nanoparticle vaccine resulted in only faintly induced humoral immunity, supporting the possibility of imprinted immunity.
The emergence of SARS-CoV-2 Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron subvariants. The concept of "imprinted immunity" suggests that individuals vaccinated with ancestral virus-based vaccines may not develop effective immunity against newly emerging Omicron subvariants, such as BQ.1.1 and XBB.1. Here, we investigated this possibility using hamsters. While natural infection induced effective antiviral immunity, breakthrough infections in hamsters with BQ.1.1 and XBB.1 Omicron subvariants after receiving the 3-dose mRNA-LNP vaccine resulted in only faintly induced humoral immunity, supporting the possibility of imprinted immunity.
Author Tabata, Koshiro
Tamura, Tomokazu
Kishimoto, Mai
Uriu, Keiya
Sato, Kei
Kida, Izumi
Fujita, Shigeru
Pan, Lin
Matsuno, Keita
Fukuhara, Takasuke
Nao, Naganori
Itakura, Yukari
Ito, Jumpei
Sawa, Hirofumi
Author_xml – sequence: 1
  givenname: Shigeru
  surname: Fujita
  fullname: Fujita, Shigeru
– sequence: 2
  givenname: Keiya
  surname: Uriu
  fullname: Uriu, Keiya
– sequence: 3
  givenname: Lin
  surname: Pan
  fullname: Pan, Lin
– sequence: 4
  givenname: Naganori
  surname: Nao
  fullname: Nao, Naganori
– sequence: 5
  givenname: Koshiro
  surname: Tabata
  fullname: Tabata, Koshiro
– sequence: 6
  givenname: Mai
  surname: Kishimoto
  fullname: Kishimoto, Mai
– sequence: 7
  givenname: Yukari
  surname: Itakura
  fullname: Itakura, Yukari
– sequence: 8
  givenname: Hirofumi
  surname: Sawa
  fullname: Sawa, Hirofumi
– sequence: 9
  givenname: Izumi
  surname: Kida
  fullname: Kida, Izumi
– sequence: 10
  givenname: Tomokazu
  surname: Tamura
  fullname: Tamura, Tomokazu
– sequence: 12
  givenname: Takasuke
  surname: Fukuhara
  fullname: Fukuhara, Takasuke
– sequence: 13
  givenname: Jumpei
  surname: Ito
  fullname: Ito, Jumpei
– sequence: 14
  givenname: Keita
  surname: Matsuno
  fullname: Matsuno, Keita
– sequence: 15
  givenname: Kei
  orcidid: 0000-0003-4431-1380
  surname: Sato
  fullname: Sato, Kei
  email: keisato@g.ecc.u-tokyo.ac.jp
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37369369$$D View this record in MEDLINE/PubMed
BookMark eNqFUV1LHDEUDUWpq-1rHyXgiz6M5mPyMU-yiK0L2kLR0reQzYdmmUnWyYx0_72xu0oriBC4l-Sck3vu2QVbMUUHwBeMjjFq6EmI3oZ8sgjaEoo-gAlmVFScY7oFJggRUmHZNDtgN-cFQqimXHwEO1RQ3pQzAb9n3VKbASYPS9eHODhbum6MYVjBWbSjKRfzFex-fp_CX9qYEPUQUoQhQh3h-Z-l60Pn4qBbOI2hK-UqWdd-Attet9l93tQ9cPP1_Prsorr88W12Nr2sDMPNUM2t8I5xymveaMkcpqZm0nLJBefSaOK5mFNbXBHLsRXcM0EJ8k3tkSBS0z1wutZdjvPOWVMm6XWripVO9yuVdFD_v8Rwp27Tg8KISVJ2UxQONwp9uh9dHlQXsnFtq6NLY1ZEUsQFYQQX6MEr6CKNfSz-FEW0kRJTxApq_9-RXmZ53noBHK8Bpk85986_QDBST7GqdaxqE2sh1K8IJgx_YyiWQvs27WhNS-PyvS8eATwVty8
CitedBy_id crossref_primary_10_1038_s41392_025_02154_6
crossref_primary_10_1128_mbio_03220_23
crossref_primary_10_1111_eci_14136
crossref_primary_10_1080_22221751_2023_2270069
crossref_primary_10_1002_jha2_932
crossref_primary_10_1038_s41392_024_02025_6
Cites_doi 10.1038/s41586-020-2798-3
10.1126/science.adc9127
10.1056/NEJMc2213907
10.1126/science.abe8499
10.1016/j.cell.2022.09.018
10.1056/NEJMoa2114583
10.1038/s41467-023-38188-z
10.1126/science.abq1841
10.1056/NEJMp2215780
10.1038/s41467-023-38345-4
10.1038/s41467-023-38435-3
10.1016/S1473-3099(23)00051-8
10.1038/s41586-022-04465-y
ContentType Journal Article
Contributor Hashiguchi, Takao
Shibatani, Yuki
Yoshida, Isao
Deguchi, Sayaka
Mugita, Yuka
Misawa, Naoko
Ito, Hayato
Tsuda, Masumi
Asakura, Hiroyuki
Takahashi, Otowa
Kawabata, Ryoko
Kimura, Kanako
Tolentino, Jarel Elgin M
Shimizu, Ryo
Suzuki, Saori
Ikeda, Terumasa
Begum, M S T Monira
Ichihara, Kimiko
Chiba, Mika
Yoshimura, Ryo
Hinay, Alfredo A
Chen, Luo
Horisawa, Yoshihito
Yasuhara, Naoko
Takayama, Kazuo
Nishiuchi, Tomoko
Oda, Yoshikata
Hashimoto, Rina
Ferdous, Zannatul
Shirakawa, Kotaro
Sakamoto, Ayaka
Tanaka, Shinya
Plianchaisuk, Arnon
Toyoda, Mako
Kaku, Yu
Nakajima, Yukari
Ohsumi, Naomi
Watanabe, Yukio
Nakagawa, So
Guo, Ziyi
Tashiro, Yusuke
Tanaka, Shiho
Yasuda, Kyoko
Nagashima, Mami
Yoshimura, Kazuhisa
Suganami, Mai
Shofa, Maya
Tabata, Kaori
Strange, Adam P
Jonathan, Michael
Shishido, Kenji
Nasser, Hesham
Saito, Akatsuki
Sasaki, Jiei
Iida, Keiko
Takaori-Kondo, Akifumi
Nomura, Ryosuke
Kawai, Yugo
Motozono, Chihiro
Nagata, Kayoko
Ueno, Takamasa
Irie, Takashi
Suzuki, Tateki
Suzuki, Rigel
Wang, Lei
Sadamasu, Kenji
Yajima, Hisano
Contributor_xml – sequence: 1
  givenname: Yu
  surname: Kaku
  fullname: Kaku, Yu
– sequence: 2
  givenname: Naoko
  surname: Misawa
  fullname: Misawa, Naoko
– sequence: 3
  givenname: Arnon
  surname: Plianchaisuk
  fullname: Plianchaisuk, Arnon
– sequence: 4
  givenname: Ziyi
  surname: Guo
  fullname: Guo, Ziyi
– sequence: 5
  givenname: Alfredo A
  surname: Hinay
  fullname: Hinay, Alfredo A
– sequence: 6
  givenname: Jarel Elgin M
  surname: Tolentino
  fullname: Tolentino, Jarel Elgin M
– sequence: 7
  givenname: Luo
  surname: Chen
  fullname: Chen, Luo
– sequence: 8
  givenname: Mai
  surname: Suganami
  fullname: Suganami, Mai
– sequence: 9
  givenname: Mika
  surname: Chiba
  fullname: Chiba, Mika
– sequence: 10
  givenname: Ryo
  surname: Yoshimura
  fullname: Yoshimura, Ryo
– sequence: 11
  givenname: Kyoko
  surname: Yasuda
  fullname: Yasuda, Kyoko
– sequence: 12
  givenname: Keiko
  surname: Iida
  fullname: Iida, Keiko
– sequence: 13
  givenname: Naomi
  surname: Ohsumi
  fullname: Ohsumi, Naomi
– sequence: 14
  givenname: Adam P
  surname: Strange
  fullname: Strange, Adam P
– sequence: 15
  givenname: Shiho
  surname: Tanaka
  fullname: Tanaka, Shiho
– sequence: 16
  givenname: Rigel
  surname: Suzuki
  fullname: Suzuki, Rigel
– sequence: 17
  givenname: Saori
  surname: Suzuki
  fullname: Suzuki, Saori
– sequence: 18
  givenname: Hayato
  surname: Ito
  fullname: Ito, Hayato
– sequence: 19
  givenname: Shinya
  surname: Tanaka
  fullname: Tanaka, Shinya
– sequence: 20
  givenname: Masumi
  surname: Tsuda
  fullname: Tsuda, Masumi
– sequence: 21
  givenname: Lei
  surname: Wang
  fullname: Wang, Lei
– sequence: 22
  givenname: Yoshikata
  surname: Oda
  fullname: Oda, Yoshikata
– sequence: 23
  givenname: Zannatul
  surname: Ferdous
  fullname: Ferdous, Zannatul
– sequence: 24
  givenname: Kenji
  surname: Shishido
  fullname: Shishido, Kenji
– sequence: 25
  givenname: Kenji
  surname: Sadamasu
  fullname: Sadamasu, Kenji
– sequence: 26
  givenname: Kazuhisa
  surname: Yoshimura
  fullname: Yoshimura, Kazuhisa
– sequence: 27
  givenname: Hiroyuki
  surname: Asakura
  fullname: Asakura, Hiroyuki
– sequence: 28
  givenname: Isao
  surname: Yoshida
  fullname: Yoshida, Isao
– sequence: 29
  givenname: Mami
  surname: Nagashima
  fullname: Nagashima, Mami
– sequence: 30
  givenname: So
  surname: Nakagawa
  fullname: Nakagawa, So
– sequence: 31
  givenname: Kotaro
  surname: Shirakawa
  fullname: Shirakawa, Kotaro
– sequence: 32
  givenname: Akifumi
  surname: Takaori-Kondo
  fullname: Takaori-Kondo, Akifumi
– sequence: 33
  givenname: Kayoko
  surname: Nagata
  fullname: Nagata, Kayoko
– sequence: 34
  givenname: Ryosuke
  surname: Nomura
  fullname: Nomura, Ryosuke
– sequence: 35
  givenname: Yoshihito
  surname: Horisawa
  fullname: Horisawa, Yoshihito
– sequence: 36
  givenname: Yusuke
  surname: Tashiro
  fullname: Tashiro, Yusuke
– sequence: 37
  givenname: Yugo
  surname: Kawai
  fullname: Kawai, Yugo
– sequence: 38
  givenname: Kazuo
  surname: Takayama
  fullname: Takayama, Kazuo
– sequence: 39
  givenname: Rina
  surname: Hashimoto
  fullname: Hashimoto, Rina
– sequence: 40
  givenname: Sayaka
  surname: Deguchi
  fullname: Deguchi, Sayaka
– sequence: 41
  givenname: Yukio
  surname: Watanabe
  fullname: Watanabe, Yukio
– sequence: 42
  givenname: Ayaka
  surname: Sakamoto
  fullname: Sakamoto, Ayaka
– sequence: 43
  givenname: Naoko
  surname: Yasuhara
  fullname: Yasuhara, Naoko
– sequence: 44
  givenname: Takao
  surname: Hashiguchi
  fullname: Hashiguchi, Takao
– sequence: 45
  givenname: Tateki
  surname: Suzuki
  fullname: Suzuki, Tateki
– sequence: 46
  givenname: Kanako
  surname: Kimura
  fullname: Kimura, Kanako
– sequence: 47
  givenname: Jiei
  surname: Sasaki
  fullname: Sasaki, Jiei
– sequence: 48
  givenname: Yukari
  surname: Nakajima
  fullname: Nakajima, Yukari
– sequence: 49
  givenname: Hisano
  surname: Yajima
  fullname: Yajima, Hisano
– sequence: 50
  givenname: Takashi
  surname: Irie
  fullname: Irie, Takashi
– sequence: 51
  givenname: Ryoko
  surname: Kawabata
  fullname: Kawabata, Ryoko
– sequence: 52
  givenname: Kaori
  surname: Tabata
  fullname: Tabata, Kaori
– sequence: 53
  givenname: Terumasa
  surname: Ikeda
  fullname: Ikeda, Terumasa
– sequence: 54
  givenname: Hesham
  surname: Nasser
  fullname: Nasser, Hesham
– sequence: 55
  givenname: Ryo
  surname: Shimizu
  fullname: Shimizu, Ryo
– sequence: 56
  givenname: M S T Monira
  surname: Begum
  fullname: Begum, M S T Monira
– sequence: 57
  givenname: Michael
  surname: Jonathan
  fullname: Jonathan, Michael
– sequence: 58
  givenname: Yuka
  surname: Mugita
  fullname: Mugita, Yuka
– sequence: 59
  givenname: Otowa
  surname: Takahashi
  fullname: Takahashi, Otowa
– sequence: 60
  givenname: Kimiko
  surname: Ichihara
  fullname: Ichihara, Kimiko
– sequence: 61
  givenname: Takamasa
  surname: Ueno
  fullname: Ueno, Takamasa
– sequence: 62
  givenname: Chihiro
  surname: Motozono
  fullname: Motozono, Chihiro
– sequence: 63
  givenname: Mako
  surname: Toyoda
  fullname: Toyoda, Mako
– sequence: 64
  givenname: Akatsuki
  surname: Saito
  fullname: Saito, Akatsuki
– sequence: 65
  givenname: Maya
  surname: Shofa
  fullname: Shofa, Maya
– sequence: 66
  givenname: Yuki
  surname: Shibatani
  fullname: Shibatani, Yuki
– sequence: 67
  givenname: Tomoko
  surname: Nishiuchi
  fullname: Nishiuchi, Tomoko
Copyright The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023
The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023
– notice: The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
CorporateAuthor The Genotype to Phenotype Japan (G2P-Japan) Consortium
Genotype to Phenotype Japan (G2P-Japan) Consortium
CorporateAuthor_xml – name: The Genotype to Phenotype Japan (G2P-Japan) Consortium
– name: Genotype to Phenotype Japan (G2P-Japan) Consortium
DBID TOX
AAYXX
CITATION
NPM
K9.
NAPCQ
7X8
5PM
DOI 10.1093/infdis/jiad230
DatabaseName Oxford Journals Open Access Collection
CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList
CrossRef

MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: TOX
  name: Oxford Journals Open Access Collection
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1537-6613
EndPage 1065
ExternalDocumentID PMC10582899
37369369
10_1093_infdis_jiad230
10.1093/infdis/jiad230
Genre Journal Article
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: JP223fa727002
– fundername: ;
  grantid: 21H02736
– fundername: ;
  grantid: JP22fk0108146; JP21fk0108493; JP22fk0108617; JP21fk0108494; JP21fk0108425; JP21fk0108432
– fundername: ;
  grantid: JPMJSP2108
– fundername: ;
  grantid: JPMJCR20H4
– fundername: ;
  grantid: JP22fk0410039
– fundername: ;
  grantid: JP22wm0125008
– fundername: ;
  grantid: 223fa627005h0001
– fundername: ;
  grantid: 22J11578
GroupedDBID ---
-DZ
-~X
..I
.2P
.55
.GJ
.I3
.XZ
.ZR
08P
0R~
123
1KJ
1TH
29K
2AX
2WC
36B
3O-
4.4
41~
48X
53G
5GY
5RE
5VS
5WD
6.Y
70D
85S
AABZA
AACGO
AACZT
AAHBH
AAHTB
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
AAYOK
ABBHK
ABDPE
ABEJV
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPLY
ABPPZ
ABPTD
ABQLI
ABQNK
ABSAR
ABSMQ
ABTLG
ABWST
ABXSQ
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACGOD
ACMRT
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ACZBC
ADACV
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFNX
AFFZL
AFHKK
AFIYH
AFOFC
AFSHK
AFXAL
AFXEN
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AI.
AIAGR
AIJHB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APJGH
APWMN
AQDSO
AQKUS
AQVQM
ATGXG
AVNTJ
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BR6
BTRTY
BVRKM
BZKNY
C45
CDBKE
CS3
CZ4
D-I
DAKXR
DCCCD
DIK
DILTD
DOOOF
DU5
D~K
EBS
ECGQY
EE~
EIHJH
EJD
EMOBN
ENERS
ESX
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HQ3
HTVGU
HW0
HZ~
IH2
IOX
IPSME
J21
J5H
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JSODD
JST
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
LSO
LU7
M49
MBLQV
MHKGH
MJL
ML0
MVM
N4W
N9A
NEJ
NGC
NOMLY
NOYVH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P0-
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TMA
TOX
TR2
VH1
W2D
W8F
WH7
X7H
X7M
Y6R
YAYTL
YKOAZ
YXANX
ZE2
ZGI
ZKG
ZXP
~91
AAYXX
ABDFA
ABGNP
ABPQP
ABVGC
ADNBA
AEMQT
AGORE
AHGBF
AHMMS
AJBYB
AJNCP
ALXQX
CITATION
JXSIZ
NPM
YIF
K9.
NAPCQ
7X8
5PM
ID FETCH-LOGICAL-c519t-bd7fe5636469a85e13c458d6867668ca2f67b3d1532d61d76f57320f94f0728a3
IEDL.DBID TOX
ISSN 0022-1899
1537-6613
IngestDate Thu Aug 21 18:36:04 EDT 2025
Thu Jul 10 19:19:34 EDT 2025
Mon Jun 30 10:42:17 EDT 2025
Wed Feb 19 02:23:49 EST 2025
Thu Apr 24 22:59:23 EDT 2025
Tue Jul 01 01:31:37 EDT 2025
Tue Nov 26 05:59:59 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords SARS-CoV-2
omicron
imprinted immunity
mRNA vaccine
Omicron
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
https://creativecommons.org/licenses/by-nc-nd/4.0
The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c519t-bd7fe5636469a85e13c458d6867668ca2f67b3d1532d61d76f57320f94f0728a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Potential conflicts of interest. SF has an honorarium for a lecture from ROYAL CANIN JAPON, Inc. NN has consulting fees from Fasmac Co., Ltd. HS has royalties from Shionogi & Co., Ltd., honoraria for lectures from Tenshi College, and is a coinventor of a patent (JP 7236065 B1, “Pharmaceutical composition containing triazine derivative”). JI has consulting fees and honoraria for lectures from Takeda Pharmaceutical Co. Ltd. KS has consulting fees from Moderna Japan Co., Ltd. and Takeda Pharmaceutical Co. Ltd. and honoraria for lectures from Gilead Sciences, Inc., Moderna Japan Co., Ltd., and Shionogi & Co., Ltd. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
K. M. and K. S. contributed equally to this study.
ORCID 0000-0003-4431-1380
OpenAccessLink https://dx.doi.org/10.1093/infdis/jiad230
PMID 37369369
PQID 3039881305
PQPubID 41591
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10582899
proquest_miscellaneous_2830672521
proquest_journals_3039881305
pubmed_primary_37369369
crossref_primary_10_1093_infdis_jiad230
crossref_citationtrail_10_1093_infdis_jiad230
oup_primary_10_1093_infdis_jiad230
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-10-18
PublicationDateYYYYMMDD 2023-10-18
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-18
  day: 18
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Oxford
PublicationTitle The Journal of infectious diseases
PublicationTitleAlternate J Infect Dis
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Krammer (2023101809352424900_jiad230-B1) 2020; 586
Park (2023101809352424900_jiad230-B13) 2022; 378
Kimura (2023101809352424900_jiad230-B5) 2022; 185
2023101809352424900_jiad230-B2
Levin (2023101809352424900_jiad230-B15) 2021; 385
Tamura (2023101809352424900_jiad230-B7) 2023; 14
Kaku (2023101809352424900_jiad230-B16) 2023; 14
Uriu (2023101809352424900_jiad230-B8) 2023; 23
Reynolds (2023101809352424900_jiad230-B11) 2022; 377
Hou (2023101809352424900_jiad230-B3) 2020; 370
Ito (2023101809352424900_jiad230-B6) 2023; 14
World Health Organization (2023101809352424900_jiad230-B4)
Offit (2023101809352424900_jiad230-B9) 2023; 388
Wang (2023101809352424900_jiad230-B10) 2023; 388
Cao (2023101809352424900_jiad230-B12) 2023; 614
Liu (2023101809352424900_jiad230-B14) 2022; 603
References_xml – volume: 586
  start-page: 516
  year: 2020
  ident: 2023101809352424900_jiad230-B1
  article-title: SARS-CoV-2 vaccines in development
  publication-title: Nature
  doi: 10.1038/s41586-020-2798-3
– volume: 378
  start-page: 619
  year: 2022
  ident: 2023101809352424900_jiad230-B13
  article-title: Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
  publication-title: Science
  doi: 10.1126/science.adc9127
– volume: 388
  start-page: 567
  year: 2023
  ident: 2023101809352424900_jiad230-B10
  article-title: Antibody response to Omicron BA.4-BA.5 bivalent booster
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2213907
– volume: 614
  start-page: 521
  year: 2023
  ident: 2023101809352424900_jiad230-B12
  article-title: Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
  publication-title: Nature
– ident: 2023101809352424900_jiad230-B4
– volume: 370
  start-page: 1464
  year: 2020
  ident: 2023101809352424900_jiad230-B3
  article-title: SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
  publication-title: Science
  doi: 10.1126/science.abe8499
– volume: 185
  start-page: 3992
  year: 2022
  ident: 2023101809352424900_jiad230-B5
  article-title: Virological characteristics of the novel SARS-CoV-2 omicron variants including BA.4 and BA.5
  publication-title: Cell
  doi: 10.1016/j.cell.2022.09.018
– volume: 385
  start-page: e84
  year: 2021
  ident: 2023101809352424900_jiad230-B15
  article-title: Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2114583
– ident: 2023101809352424900_jiad230-B2
– volume: 14
  start-page: 2671
  year: 2023
  ident: 2023101809352424900_jiad230-B6
  article-title: Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-38188-z
– volume: 377
  year: 2022
  ident: 2023101809352424900_jiad230-B11
  article-title: Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
  publication-title: Science
  doi: 10.1126/science.abq1841
– volume: 388
  start-page: 481
  year: 2023
  ident: 2023101809352424900_jiad230-B9
  article-title: Bivalent Covid-19 vaccines—a cautionary tale
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp2215780
– volume: 14
  start-page: 2751
  year: 2023
  ident: 2023101809352424900_jiad230-B16
  article-title: Evolution of antibody immunity following Omicron BA.1 breakthrough infection
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-38345-4
– volume: 14
  start-page: 2800
  year: 2023
  ident: 2023101809352424900_jiad230-B7
  article-title: Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-38435-3
– volume: 23
  start-page: 280
  year: 2023
  ident: 2023101809352424900_jiad230-B8
  article-title: Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(23)00051-8
– volume: 603
  start-page: 493
  year: 2022
  ident: 2023101809352424900_jiad230-B14
  article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04465-y
SSID ssj0004367
Score 2.4634461
Snippet Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may...
The emergence of SARS-CoV-2 Omicron variants has led to concerns that ancestral SARS-CoV-2-based vaccines may not be effective against newly emerging Omicron...
SourceID pubmedcentral
proquest
pubmed
crossref
oup
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1060
SubjectTerms Animal models
Antiviral drugs
Brief Report
Coronaviruses
Humoral immunity
Immunity
mRNA
Nanoparticles
Severe acute respiratory syndrome coronavirus 2
Vaccines
Title Impact of Imprinted Immunity Induced by mRNA Vaccination in an Experimental Animal Model
URI https://www.ncbi.nlm.nih.gov/pubmed/37369369
https://www.proquest.com/docview/3039881305
https://www.proquest.com/docview/2830672521
https://pubmed.ncbi.nlm.nih.gov/PMC10582899
Volume 228
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Ra9swED5KYWUvY-u6zl1atFLYk2lsWSflMYyWdqUplLbkzciSRT0SZ9TJQ_79TrbjJmFje7KxTtjoJN2dT_d9AGdoM6viSHtCE-0DFKQlJfLQJqY-EoCJqU9bjPDqMfkxFuMWLLr6Qwp_wM9ppG1Rnf8stCV_mXZbssAeJf_hbvxaAclRrnDBIwohOnjG7e4b5mejpG3Ns9w-ILlmcS7fw7vWVWTDRrcfYCcv9-FNQx653Ie92zYt_hHG13WtI5s55n8SeAgIS3e-8mO-ZJ6dw9CDbMmm96Mhe9KGutUaYUXJdMku1mD-2bAspnTxJGmTA3i8vHj4fhW2lAmhIVdsHmZWulwgR4p6tRJ5xE0ilEWFElEZHTuUGbe0zcUWIyvRCcnjvhskri9jpfkn2C1nZf4ZWNaXuRNWo40zXx47ENwpw5VIYudQyADC1UimpsUT97QWk7TJa_O0Gfm0HfkAvnXyvxokjb9KnpJi_inUW-ktbZddlZI9HihFZlkE8LVrpgXjsyC6zGeLKvWIZyhjclsCOGzU3L2KS46e4TAAtTEBOgEPxr3ZUhbPNSg3-al18Hr0Px__Bd562npvAyPVg935yyI_Judmnp2QW399c1LP7t-vu_j0
linkProvider Oxford University Press
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+Imprinted+Immunity+Induced+by+mRNA+Vaccination+in+an+Experimental+Animal+Model&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Fujita%2C+Shigeru&rft.au=Uriu%2C+Keiya&rft.au=Pan%2C+Lin&rft.au=Nao%2C+Naganori&rft.date=2023-10-18&rft.pub=Oxford+University+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=228&rft.issue=8&rft.spage=1060&rft.epage=1065&rft_id=info:doi/10.1093%2Finfdis%2Fjiad230&rft.externalDocID=10.1093%2Finfdis%2Fjiad230
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon